Belite Bio Inc ADR (BLTE)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from BLTE's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from Belite Bio Inc ADR's 10-K filings. The deep dive has 15+ years, quarters and every line.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net income | -$10M | -$13M | -$32M | -$36M | -$78M |
| Free cash flow | -$8M | -$12M | -$30M | -$29M | -$37M |
| EPS (diluted) | -$1.01 | -$0.63 | -$1.19 | -$1.18 | -$2.31 |
| Operating margin | — | — | — | — | — |
Superinvestors who own BLTE
From each investor's latest 13F filing (what a 13F shows). 2 of the investors we track hold it.
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| Lee Ainslie Maverick Capital |
New position | $61M | 0.54% | Q2 2026 |
| Stanley Druckenmiller Duquesne Family Office |
Held | $16M | 0.31% | Q2 2026 |
Insider buying
Open-market purchases by Belite Bio Inc ADR's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when BLTE trades at or below it.
Free accounts get 3 price alerts. No card needed.
In the full deep dive
Questions
Are Belite Bio Inc ADR insiders buying the stock?
No open-market insider purchases of BLTE in the last 12 months, according to SEC Form 4 filings.
Which superinvestors own Belite Bio Inc ADR?
2 of the superinvestors Investingly tracks hold BLTE in their latest 13F, including Lee Ainslie, Stanley Druckenmiller.
Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.